Hello,
Welcome to Insider Healthcare. I'm Lydia Ramsey Pflanzer, and today in healthcare news:
- These are the investors that stand to make the most as Bright Health goes public;
- The "supertaster" gene might be linked to protection against COVID-19;
- The US has passed 600,000 coronavirus deaths.
If you're new to this newsletter, sign up here. Comments, tips? Email me at [email protected] or tweet @lydiaramsey125. Let's get to it…
Bright Health is going public at a $13.4 billion valuation. Here are the investors and execs who stand to make the most in the health insurance upstart's IPO.
- Bright Health is going public at a $13.4 billion valuation.
- The health insurance upstart listed its top investors and executives in its S-1 filing.
Here's which investors and execs stand to make the most>>
A 'supertaster' gene that makes people more sensitive to bitter flavors may also help protect against COVID-19
- The T2R38 gene makes people more sensitive to bitter tastes and also enhances immune function.
- It has been linked to stronger immunity against infections. Research suggests that includes COVID-19.
- "Supertasters" with two copies of the gene may be less likely to get COVID-19 and develop severe illness.
The US coronavirus death toll has passed 600,000, according to Johns Hopkins University data
- The US death toll from COVID-19 has passed 600,000, according to data from Johns Hopkins University.
- Pre-pandemic life has largely returned in the US because of the vaccine rollout.
- But some vaccine hesitancy and procrastination is posing a threat to reaching herd immunity.
More stories we're reading:
- Bright Health's S-1 filing reveals its bonkers revenue growth, dealmaking spree, and a foray into clinics. (Insider)
- Some states had coronavirus infections before cases were officially reported (Reuters)
- Graph shows how US COVID-19 spikes track strongly with the places where people are refusing vaccinations (Insider)
- Amazon's COVID-19 test is now available online for consumers (Stat News)
- Lydia
Read the original article on Business Insider